This weak GnRH agonist binds to GnRH receptors (GnRH-R) on cancer cells and induces, like GnRH-I, a direct antitumor activity on several cancer cell lines, but its gonadotropin releasing activity is 500–1000 times lower in vitro and in vivo [5,6]. The gene discussed is GNRH1; the disease is cancer.